ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten | Dr Rader

Подробнее о видео

Watch on Radcliffe Cardiology:

This interview with Dr Florian Rader (Cedars-Sinai Medical Center, Los Angeles, CA, US) focuses on the interim results of the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655). This study is the largest and longest report of mavacamten that investigated 310 patients with symptomatic obstructive HCM for over 252 weeks.
Originally presented at the ACC 2022, these results show that treatment with mavacamten resulted in significant reductions in left ventricular outflow tract gradients and significant improvement in NYHA functional class in patients with obstructive HCM after 63 weeks.

Discussion Points:
-Importance of this study
-Study design and patient cohort
-Key findings
-Considerations for use
-Take-home messages
-Further research required

Recorded remotely from Brisbane, 2022.
Interviewer: Jordan Rance

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.